Why the study?
Is an automatic implantable cardioverter defibrillator a reasonable therapeutic option for patients with doxorubicin-associated cardiomyopathy who survive cardiac arrest?
Is an automatic implantable cardioverter defibrillator a reasonable therapeutic option for patients with doxorubicin-associated cardiomyopathy who survive cardiac arrest?
AICD implantation appears to be a reasonable therapeutic option for patients with doxorubicin-associated dilated cardiomyopathy who survive cardiac arrest, even if electrophysiological studies are negative.
Answers are grounded in this paper and cite their sources.
May support AICD consideration despite negative EPS; leaves open need for prospective validation in doxorubicin cardiomyopathy.
Two patients who survived cardiac arrest late after doxorubicin administration are described. Both patients had nonischemic, dilated cardiomyopathies and underwent electrophysiological studies during which no ventricular arrhythmias were induced. Their negative electrophysiological studies despite well documented cardiac arrests and subsequent clinical courses suggest that patients with cardiomyopathies after doxorubicin administra tion and dilated cardiomyopathies of other etiologies have similar natural histories. Treatment with an automatic implantable cardioverter defibrillator appears to be a reasonable therapeutic option for patients with anthracyline associated cardiac disease who have survived their malignancy but at the price of developing life‐threatening arrhythmias.
No takes yet. Share an insight, caveat, or question.
Epstein et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: